Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.

Ziepert, Marita

Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology May 2010 - 2373-80 p. digital

Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1527-7755

10.1200/JCO.2009.26.2493 doi


Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Murine-Derived
Antigens, CD20--immunology
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Computer Simulation
Cyclophosphamide--administration & dosage
Disease Progression
Disease-Free Survival
Doxorubicin--administration & dosage
Female
Health Status Indicators
Humans
Kaplan-Meier Estimate
Lymphoma, B-Cell--diagnosis
Male
Middle Aged
Predictive Value of Tests
Prednisone--administration & dosage
Proportional Hazards Models
Prospective Studies
Risk Assessment
Risk Factors
Rituximab
Time Factors
Treatment Outcome
Vincristine--administration & dosage
Young Adult